Results 61 to 70 of about 7,203,066 (311)

Drug Court Process Evaluation Report, February 2008 [PDF]

, 2008
The Iowa Consortium for Substance Abuse Research and Evaluation conducted a process evaluation in 2007 on the seven adult and juvenile drug courts existing in Iowa in 2003.

core  

KDM7A and KDM1A inhibition suppresses tumour promoting pathways in prostate cancer

Molecular Oncology, EarlyView.
Treatment resistance is a major challenge for patients with advanced prostate cancer. This study examined an alternative approach to target the major prostate cancer‐promoting pathway by targeting epigenetic factors, whose levels are higher in tumours.
Jennie N Jeyapalan, Veronika M Metzler, Simone de Brot, Corinne L Woodcock, Anna E Harris, Jennifer Lothion‐Roy, Emeli M Nilsson, Atara Ntekim, Michael S Toss, Jenny L Persson, Francesca Khani, Brian D Robinson, Lorraine J Gudas, Emad Rakha, David M Heery, Catrin S Rutland, Nigel P Mongan   +16 more
wiley   +1 more source

Nanocrown electrodes for parallel and robust intracellular recording of cardiomyocytes

Nature Communications, 2022
Nanoelectrodes for measuring intracellular action potentials suffer from issues with success rate, signal strength and fabrication. Here, the authors report on a scalable technique which creates robust nanocrown electrodes with high success rates by ...
Zeinab Jahed, Yang Yang, Ching-Ting Tsai, Ethan P. Foster, Allister F. McGuire, Huaxiao Yang, Aofei Liu, Csaba Forro, Zen Yan, Xin Jiang, Ming-Tao Zhao, Wei Zhang, Xiao Li, Thomas Li, Annalisa Pawlosky, Joseph C. Wu, Bianxiao Cui   +16 more
doaj   +1 more source

Preclinical pharmacodynamic evaluation of antibiotic nitroxoline for anticancer drug repurposing

Oncology Letters, 2016
The established urinary antibiotic nitroxoline has recently regained considerable attention, due to its potent activities in inhibiting angiogenesis, inducing apoptosis and blocking cancer cell invasion. These features make nitroxoline an excellent candidate for anticancer drug repurposing.
ZHANG, QI, WANG, SHANSHAN, YANG, DEXUAN, PAN, KEVIN, LI, LINNA, YUAN, SHOUJUN   +5 more
openaire   +3 more sources

Transcriptional profiling of circulating extracellular vesicles from prebiopsy prostate cancer patients

Molecular Oncology, EarlyView.
RNA profiling of circulating extracellular vesicles (EVs) from blood samples of men undergoing prostate biopsy identifies transcripts associated with clinically significant prostate cancer. Integrative analysis with public tumor datasets links EV‐derived gene signatures to tumor stage and progression‐free survival, highlighting CASP3, XRCC2, and RIT1 ...
Stefan Werner, Pierre Tennstedt, Randi C. Pose, Christian Müller, Katharina Besler, Svenja Schneegans, Malik Alawi, Marie C. Roesch, Sven Peine, Desiree Bonci, Joanna Budna‐Tukan, Evi Lianidou, Catherine Alix‐Panabières, Derya Tilki, Klaus Pantel   +14 more
wiley   +1 more source

Introduction to drug utilization research [PDF]

, 2003
Prepared by the WHO Collaborating Centre for Drug Statistics Methodology, the WHO Collaborating Centre for Drug Utilization Research and Clinical Pharmacological Services, and the International Working Group for Drug Statistics Methodology48 p.Korean ...
WHO International Working Group for Drug Statistics Methodology, WHO Collaborating Centre for Drug Statistics Methodology, WHO Collaborating Centre for Drug Utilization Research and Clinical Pharmacological Services   +2 more
core  

Locoregional cancer therapy using polymer-based drug depots [PDF]

, 2016
Locoregional delivery of anticancer drugs is an attractive approach to minimize adverse effects associated with intravenous chemotherapy. Polymer-based drug depots injected or implanted intratumorally or adjacent to the tumor can provide long-term local ...
Kiessling, F., Pharmaceutics, Storm, Gerrit, Kok, Robbert J., Sub Drug delivery, van Nostrum, Cornelis F., Lammers, Twan Gerardus Gertudis Maria, Sub Drug targeting, Hennink, W.E., Kiessling, Fabian, Hennink, Wim E., Dep Farmaceutische wetenschappen, van Nostrum, C.F., Lammers, Twan, Kok, R.J., Storm, G, Storm, Gert, Ramazani, Farshad, Ramazani, F.   +18 more
core   +2 more sources

Stimulator of interferon genes agonist augmented antitumor immunity of osimertinib in Egfr‐mutated lung cancer

Molecular Oncology, EarlyView.
Combining osimertinib with the STING agonist ADU‐S100 activates innate and adaptive immunity to overcome the non‐inflamed microenvironment of Egfr‐mutant lung cancer. This combination increases NK and CD8+ T‐cell infiltration, associated with activation of the STING‐IRF3 pathway and local immunogenic cell death.
Jun Nishimura, Tadahiro Kuribayashi, Johannes Brägelmann, Sachi Okawa, Masataka Taoka, Shunta Mori, Tomoka Nishimura, Takaaki Tanaka, Go Makimoto, Kiichiro Ninomiya, Kammei Rai, Eiki Ichihara, Ryohei Katayama, Katsuyuki Hotta, Masahiro Tabata, Yosuke Togashi, Yoshinobu Maeda, Martin L. Sos, Katsuyuki Kiura, Kadoaki Ohashi   +19 more
wiley   +1 more source

A novel quinazolinone insulin receptor inhibitor and its synergy with an EGFR inhibitor in glucose‐driven glioblastoma

Molecular Oncology, EarlyView.
The novel styrylquinazolinone‐based molecule W1B effectively suppresses glioblastoma by inhibiting IGF1R and EGFR. In high‐glucose microenvironments driving tumor resistance, W1B acts synergistically with the EGFR inhibitor dacomitinib. This combination safely blocks compensatory survival signaling in zebrafish xenograft models. Showcasing promising in
Patryk Rurka, Wioleta Cieślik, Wojciech Płaziński, Katarzyna Stępnik, Anna Boguszewska‐Czubara, Elżbieta Kot, Robert Musioł, Mateusz Jasica, Anna Mrozek‐Wilczkiewicz, Katarzyna Malarz   +9 more
wiley   +1 more source

Selecting an evaluation consultant or team [PDF]

, 2012
French version available in IDRC Digital Library: Choix de l’évaluateur ou de l’équipe d'évaluationRegardless of the evaluation topic and intended use, the most important general characteristics to consider when selecting an external evaluator are ...
IDRC. Evaluation Unit
core   +1 more source